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Abstract

Introduction
Phenytoin has complex pharmacokinetics. The intravenous loading dose of phenytoin for children in status epilepticus has recently been increased from 18 to 20mg/kg.  There are no data on the clinical effectiveness and safety of this new dose.  
Methods
The use of intravenous loading doses of phenytoin was audited over 27 months to evaluate the pharmacokinetic, clinical and toxic effects of the new dose in clinical practice. Serum phenytoin concentrations were compared with both dose (weight-adjusted) and time.  
Results
Serum phenytoin concentrations were measured on 48 occasions from 41 children (39 retrospective and 9 prospective), of which 24 were within 60-180 (median 105) minutes following completion of infusion of the loading dose. Use of estimated weights meant patients received between 15.5 and 27.5mg/kg (78-138% expected dose).  Supra-therapeutic serum concentrations (>20µg/ml were present in 5/24 (20.1%) (after doses based on actual weight in three, and estimated weight in two patients).  Three adverse effects consistent with phenytoin toxicity were noted in children with supra-therapeutic concentrations. Two errors in dose prescriptions were found.
Conclusion
The majority of serum phenytoin concentrations were in the therapeutic range.  Estimating weight in children for the 20mg/kg intravenous loading dose of phenytoin is often clinically necessary but inaccurate, resulting in up to 138% of the expected and recommended dose in this cohort. 


Introduction

The recommended intravenous phenytoin loading dose for paediatric convulsive status epilepticus (CSE) in the UK was increased from 18mg/kg to 20mg/kg (January 2011), to reduce the theoretical risk of miscalculation []. This regime has since been adopted across Europe and the USA. 

Phenytoin has a narrow therapeutic range (10-20 µg/ml), and non-linear pharmacokinetics [].  The intravenous 18mg/kg loading dose has been shown to maintain the phenytoin serum concentration in this range  ADDIN EN.CITE [, ], but there are no equivalent data on the 20 mg/kgdose.  Phenytoin can induce potentially fatal cardiac arrhythmias, hypotension and neurological side effects, particularly at higher serum concentrations [].
  
We felt it important to evaluate the new dose and assess serum concentrations within the context of effectiveness and toxicity [4].
Method

An audit was undertaken of all patients who received an intravenous loading dose of phenytoin to treat an acute generalised tonic-clonic or other seizure.  The audit was registered in the Hospital’s Audit Department.  Data were collected prospectively from 1st October 2012 to 1st April 2013 and retrospectively from 1 Jan 2011 to 30th September 2012. 

Current clinical practice at our institution is to measure the total serum phenytoin concentrations  between one and three  hours following infusion of the intravenous  loading dose [] and to aim for a blood concentration of 10-20µg/ml. 

For retrospective data, patients were identified using the Trust computer system, nursing and medical notes and clinic letters and included indication, effectiveness, dose and possible side effects. For prospective data, new patients were identified through new requests identified by the Clinical Chemistry, A+E, neurology and intensive care departments and information obtained from medical case notes.  


Results 

Retrospective screening identified 47 measurements, eight of which were excluded; five were receiving maintenance phenytoin, one had a previous loading dose and two had incomplete prescription data (missing dose in one; one missing case notes).  Prospective screening identified 21 patients, 12 of whom were excluded; five were receiving maintenance oral phenytoin, seven had incomplete prescription data (including four transfers to our intensive care unit from other hospitals).  Consequently, analysis was undertaken on 48 intravenous loading doses (39 retrospective, 9 prospective), from 41 patients (none of whom received phenytoin in the preceding month). Blood sample time was recorded from the case electronic computer request or case notes. Median age of children was 3.3 years (range 13 days to 20 years).

The %CV for measurements of phenytoin concentrations were between 4.0 and 6.0

The presenting seizure was generalised tonic clonic (n=32), clonic (n=1), focal (n=7), tonic (n=2) and febrile not otherwise specified (n=1). Seizure type was not documented in five cases.  

Serum phenytoin concentration was measured in 46 doses (insufficient sample in one and no sample in one).  However, only 24 concentrations were undertaken between 60 and 180 (median 105) minutes after completion of the loading dose. 

Nineteen of these were within the therapeutic range, and five were supra-therapeutic. No sub-therapeutic concentrations were identified (Figure 1). The remaining phenytoin concentrations were taken at times up to 20 hours post dose (Figure 2).

Actual weight was used to calculate the dose in 25/46 prescriptions, estimated dose in 17/46 , and data were unavailable in four . Of the five cases with supra-therapeutic blood concentrations, doses were based on actual weight in three and estimated weight in two. 

Weight was analysed on dose per kg actual weight basis (regardless of estimated or actual weight used in prescription).   Overall, 31/48 doses were between 18-22mg/kg, reflecting a ‘rounding-up’ or down to achieve a deliverable dose.  

The full range of doses prescribed was between 15.5 to 27.5 mg/kg. There were two potential prescribing errors of 22.7 and 24mg/kg, both noted after the event (one retrospectively, one prospectively).   Some variation was secondary to inaccurate weight estimation.  For estimated weights, two were below the actual weight (up to 2500 grams) and five were above (up to 7500 grams).   

In cases with samples taken between 60-180 minutes, phenytoin terminated the seizure in 19 out of 24 cases (75%) with serum concentrations from 10.8 to 32.2µg/ml. Serum concentrations were 16.2, 16.2, 13.5, 15.1, 14.8 in the five patients in whom the seizure persisted.  

Possible adverse events were recorded in 18/40 patients (one patient’s notes were missing). Most were mild and non-specific.  Significant symptoms were documented on three occasions, all in conjunction with supra-therapeutic concentrations. In retrospective patients, respiratory depression with a phenytoin concentration of 24.5µg/ml at 90 minutes (one patient)and bradycardia, oxygen desaturation and drowsiness with a phenytoin concentration of 22 µg/ml at 98 minutes (one patient).  Prospectively, vomiting, drowsiness and pyrexia with a phenytoin concentration of 33.4µg/ml at 245 minutes occurred (one patient). Finally, there were two episodes of probable toxicity with concentrations within the therapeutic range, but samples were taken at 406 minutes (retrospective patient, hypertension and twitching with a phenytoin concentration of  17.6µg/ml) and 460 minutes (prospective patient, hypotension with a phenytoin concentration of 18.6µg/ml).   

Discussion
The majority (79%) of blood concentrations were within the therapeutic range if measured between 60-180minutes; this is similar to the 77% found using 18mg/kg [].  At 20mg/kg, phenytoin was effective, terminating CSE in 75% of cases.   However, potential phenytoin toxicity was identified; in two cases these were associated with supra-therapeutic concentrations within 60-180minutes and one with a supra-therapeutic concentration measured 245minutes. 


This study has clear limitations, being based on relatively small numbers of patients and with retrospective analyses for most patients. In addition, a significant number of phenytoin concentrations were sampled or measured after 180 minutes; the reasons for this are unclear but may include measurements being postponed until normal working hours. An assessment of toxicity was difficult and was based on subjective observation and recording, which might have been biased in cases where concentrations were supra-therapeutic. Prospective patients may have been more closely monitored for signs of toxicity, whilst retrospective patients relied on case note documentation. Finally, this study has shown difficulties in determining a reliable estimated weight, leading to a range of doses.  

Overall, the study suggests that 20mg/kg results in a similar percentage of supra-therapeutic serum concentrations, but with a higher proportion of clinical toxicity than 18mg/kg. A range of doses continue to be prescribed because of errors in estimated weight (up to 138% of the expected or recommended dose). Finally, despite the effectiveness of phenytoin in treating prolonged seizures (including CSE), its variable pharmacokinetic and toxicity profiles justifies careful observation of the patient during and following administration while the drug remains in the algorithm for treating prolonged seizures and convulsive status epilepticus. 
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